MedTrace Logo

Genotypic Resistance-guided Versus Empirical Therapy for H. Pylori Eradication.

NCT04090021 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 304

Last updated 2019-09-19

No results posted yet for this study

Summary

This study aims to investigate the efficacy of a 7-day genotypic resistance-guided triple therapy, compared with empirical concomitant therapy, for first-line eradication of H. pylori.

Conditions

  • Helicobacter Pylori Infection

Interventions

DRUG

Esomeprazole 40mg

Use in a drug combination for H. pylori eradication

DRUG

Clarithromycin 500mg

Use in a drug combination for H. pylori eradication

DRUG

Metronidazole 500 mg

Use in a drug combination for H. pylori eradication

DRUG

Amoxicillin 1000 MG

Use in a drug combination for H. pylori eradication

DRUG

Levofloxacin 500mg

Use in a drug combination for H. pylori eradication

DRUG

Rifabutin 150 MG

Use in a drug combination for H. pylori eradication

Sponsors & Collaborators

  • Konstantopoulio-Patission General Hospital of Nea Ionia

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-01
Primary Completion
2020-02-28
Completion
2020-02-28

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04090021 on ClinicalTrials.gov